Assessment of the Rosacea Prevalence in the General Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-09-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-centre interventional cross-sectional prevalence study Assessment of the Rosacea Prevalence in the General Population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective:

Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rosacea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prevalence assessment

Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The following subjects will be included in the study:

* Subjects aged 18 to 65 years old from the general population
* Subjects who are willing to complete the questionnaires

Part II

The following subjects will be included in Part II of the study:

* Subjects who screened positive for rosacea during the first part of the study and selected by random method
* Subjects who gave their informed consent to participate in Part II of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fabien AUDIBERT, Bsc

Role: STUDY_DIRECTOR

Galderma R&D

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD.03.SPR.29104

Identifier Type: -

Identifier Source: org_study_id